WillItSurvive
Pharma and healthcare groups · United States

Exelixis

exelixis.com ↗

Oncology biopharma selling cabozantinib (CABOMETYX), the top-prescribed kidney cancer pill.

Defensible for now
Assessed 24 July 2026 · Evidence as of 24 July 2026
Real protection, with named pressure against it.
On the recordSince 24 July 2026 · Checkable from December 3, 2026 · Every call on the record Checkpoint: FDA PDUFA decision on zanzalintinib plus atezolizumab for metastatic colorectal cancer
The call

Exelixis runs a profitable, patent-shielded kidney cancer business now betting its next five years on one FDA decision for zanzalintinib in December 2026.

Exelixis is a public company that sells cabozantinib, a pill-form cancer drug that leads the kidney cancer market and brings in nearly half of all similar drugs sold by mouth. Rivals like Merck, Bristol Myers Squibb, Pfizer, and Roche already sell competing pills for the same cancers, so Exelixis's main shield is its patents, which will expire within a few years. The company's future pivots almost entirely on whether the FDA approves its new drug zanzalintinib in December 2026. A recent trial showed the drug did not work as well as hoped in some patient groups, making approval less certain and putting the whole investment case at risk.

Why
01
AI pressure: None apparent. AI drug-discovery labs like Isomorphic Labs could speed rivals' pipelines someday, but nothing threatens cabozantinib sales now. Could AI do the core job? Unlikely.
02
Bigger players: Bristol Myers Squibb, Merck, Roche/Genentech, Pfizer, AstraZeneca, Eisai. All sell competing kidney cancer TKIs or IO combos today, yet CABOMETYX still holds 46% of the oral TKI market. Could a giant copy it? No, they are blocked.
03
What protects it. Patent-protected cabozantinib franchise with #1 share in kidney cancer, growing NET revenue, and heavy cash for buybacks.
What would change this call
FDA decision on zanzalintinib plus atezolizumab for colorectal cancer by December 3, 2026. Approval or rejection determines whether Exelixis has a successor drug once cabozantinib patents lapse.
STELLAR-304 phase 3 readout for non-clear-cell kidney cancer (zanzalintinib plus nivolumab vs sunitinib). A negative result would weaken the case that zanzalintinib can replace cabozantinib revenue.
Exelixis discloses the exact cabozantinib patent expiration date in an SEC filing or earnings call. Clarifies how many years of protected revenue remain before generic competition arrives.
Key numbers
  • FY2025 revenue $2.320B, up 6.98% YoY (2025-12-31)
  • U.S. cabozantinib franchise revenue $2.12B, up 17% YoY (2025-12-31)
  • CABOMETYX held 46% of oral TKI market (2025-12-31)
Named risks
  • Roughly 90% of revenue concentrated in the cabozantinib franchise with unconfirmed patent expiration date. Severity: high
  • Binary FDA decision on zanzalintinib due December 3, 2026 after a June 2026 non significant subgroup result. Severity: high
  • STELLAR-304 non-clear-cell RCC readout still pending, could weaken second franchise narrative. Severity: medium
  • SEC filing headcount declined 6.1% year over year in 2025 despite upcoming product launch needs. Severity: medium
  • 2026 Medicare Part D 2% discount requirement as a designated specified small manufacturer. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Merck (Keytruda plus Lenvima)contestingCollaboration partner and RCC rival; CABOMETYX still held 46% oral TKI share as of Q4 2025
Bristol Myers Squibb (Opdivo plus Yervoy)contestingBoth collaborator in COSMIC-313 and RCC competitor as of 2025
Roche/Genentech (Tecentriq plus Avastin)losing toEstablished first line HCC dominance versus Exelixis per 2026 competitive analysis
Eisai/Merck (lenvatinib)contestingNamed in Exelixis's own TKI market basket comparison, Q4 2025 earnings call
Questions people ask
Is Exelixis profitable in 2026?
Yes. Exelixis reported FY2025 total revenue of $2.320 billion, up 6.98% year over year, with the cabozantinib franchise (CABOMETYX plus COMETRIQ) generating $2.12 to $2.123 billion in US net product revenue, up 17% YoY, as of December 31, 2025.
Who is Exelixis's biggest competitor?
Merck's Keytruda plus Lenvima and Bristol Myers Squibb's Opdivo plus Yervoy are the closest rivals to CABOMETYX in kidney cancer, while Roche's Tecentriq plus Avastin leads first line liver cancer. Despite years of competition, CABOMETYX still held 46% of the oral TKI market as of Q4 2025.
Could AI replace Exelixis's drugs?
No. Exelixis sells an FDA approved, patent protected small molecule, cabozantinib, that required randomized phase 3 trials and regulatory review. AI is used as an input, such as the 2022 Insilico Medicine licensed compound XL309, not as a substitute for the approved product itself.
Who owns Exelixis?
Exelixis has no parent company or controlling owner. It has been publicly traded since its IPO on April 7, 2000, with institutions holding about 89% of shares and insiders about 2.65% as of July 17, 2026.
What is the biggest risk facing Exelixis right now?
About 90% of revenue depends on the cabozantinib franchise, and the FDA's PDUFA decision on successor drug zanzalintinib plus atezolizumab for colorectal cancer is due December 3, 2026, after a June 2026 subgroup analysis showed a non significant survival trend, HR 0.83, p equals 0.1185.
Are there layoffs at Exelixis?
SEC filing data shows Exelixis headcount declining each year since 2023, from 1,310 to 1,147 to 1,077 employees at year end 2025, a 6.1% drop, even while the company builds its commercial sales team ahead of a possible late 2026 drug launch.
Timeline
  • 2026-06-22STELLAR-303 subgroup OS analysis shows HR 0.83, p=0.1185, not statistically significant
  • 2026-05Exelixis and Merck announce collaboration to supply Keytruda QLEX for STELLAR-316 trial
  • 2026-03-31Q1 2026 revenue reported at $611 million, up almost 10% year over year
  • 2026-02FDA accepts NDA for zanzalintinib plus atezolizumab, PDUFA date set for December 3, 2026
  • 2026-01Exelixis announces collaboration with Natera for STELLAR-316 using Signatera cfDNA assay
  • 2025-12-31FY2025 revenue closes at $2.320 billion, cabozantinib US franchise up 17% YoY
  • 2025-03FDA approves CABOMETYX for neuroendocrine tumors, adds new revenue indication
  • 2024-12-31Exelixis pays $10 million milestone as Insilico-licensed XL309 enters Phase 1
  • 2022-01Insilico Medicine licenses AI-designed USP1 inhibitor XL309 to Exelixis
  • 2000-04-07Exelixis IPOs on Nasdaq under ticker EXEL
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources